Sections

Medication

Medication Summary

The goals of therapy are to reduce morbidity, to shorten the clinical course of the disease, to prevent complications, and to prevent recurrences. Pharmacotherapy for herpes simplex encephalitis (HSE) is available in the form of acyclovir. Patient outcome is improved when this agent is used for treatment.

Class Summary

The goals of using antivirals are to shorten the clinical course, prevent complications, prevent development of latency and subsequent recurrences, decrease transmission, and eliminate established latency.

Acyclovir (Zovirax)

View full drug information

Acyclovir is the drug of choice for HSE. It has demonstrated inhibitory activity against both herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) and is taken up selectively by infected cells. Mortality from HSE before use of acyclovir was 60-70%; since acyclovir, it is approximately 30%.

Famciclovir (Famvir)

View full drug information

After ingestion, drug is rapidly biotransformed into the active compound penciclovir and phosphorylated by viral thymidine kinase. By competition with deoxyguanosine triphosphate, penciclovir triphosphate inhibits viral polymerase, subsequently inhibiting viral DNA synthesis/replication.

Adjust the dose in patients with renal insufficiency or hepatic disease.

Class Summary

Anticonvulsants are used to terminate clinical and electrical seizure activity as rapidly as possible and to prevent seizure recurrence.

Carbamazepine (Tegretol)

View full drug information

Carbamazepine is effective in treatment of complex partial seizures; it appears to act by reducing polysynaptic responses and blocking posttetanic potentiation.

Phenytoin (Dilantin, Phenytek)

View full drug information

Phenytoin is a hydantoin. Its primary site of action appears to be the motor cortex, where it may inhibit spread of seizure activity; it may reduce maximal activity of the brain stem centers responsible for the tonic phase of grand mal seizures.

The dose should be individualized; if daily dosage cannot be divided equally, larger dose should be given before bedtime. A phosphorylated formulation, fosphenytoin, is available for parenteral use.

Class Summary

These agents are used for the management of increased intracranial pressure in complications resulting from herpes simplex encephalitis.

Furosemide (Lasix)

View full drug information

Furosemide is a loop diuretic that increases the excretion of water by interfering with the chloride-binding co-transport system, which, in turn, inhibits sodium and chloride reabsorption in the ascending loop of Henle and distal renal tubule. It increases renal blood flow without increasing the filtration rate. The onset of action generally is within 1 hour. It increases potassium, sodium, calcium, and magnesium excretion.

Furosemide is used in the acute setting for reduction of increased ICP. The proposed mechanisms in lowering ICP include following: (1) suppression of cerebral sodium uptake, (2) carbonic anhydrase inhibition resulting in decreased CSF production, and (3) inhibition of cellular membrane cation-chloride pump, thereby affecting the transport of water into astroglial cells.

The dose must be individualized to the patient. Depending on the response, administer at increments of 20-40 mg, no sooner than 6-8 hours after the previous dose, until desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until a satisfactory effect is achieved.

Mannitol (Osmitrol)

View full drug information

Mannitol reduces cerebral edema with the help of osmotic forces, and it decreases blood viscosity, resulting in reflex vasoconstriction and lowering of ICP.

Questions

Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006 Sep. 71(2-3):141-8. [Medline].
Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis. 2005 Jan. 16(1):17-23. [Medline].
Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes. 2004 Jun. 11 Suppl 2:57A-64A. [Medline].
Whitley RJ, Cobbs CG, Alford CA Jr, Soong SJ, Hirsch MS, Connor JD, et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA. 1989 Jul 14. 262(2):234-9. [Medline].
Whitley RJ, Soong SJ, Linneman C Jr, Liu C, Pazin G, Alford CA. Herpes simplex encephalitis. Clinical Assessment. JAMA. 1982 Jan 15. 247(3):317-20. [Medline].
Tan IL, McArthur JC, Venkatesan A, Nath A. Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology. 2012 Nov 20. 79(21):2125-32. [Medline]. [Full Text].
Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1995 Apr. 171(4):857-63. [Medline].
Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. 1996 Oct. 61(4):339-45. [Medline]. [Full Text].
Wasay M, Mekan SF, Khelaeni B, Saeed Z, Hassan A, Cheema Z, et al. Extra temporal involvement in herpes simplex encephalitis. Eur J Neurol. 2005 Jun. 12(6):475-9. [Medline].
Aurelian L. HSV-induced apoptosis in herpes encephalitis. Curr Top Microbiol Immunol. 2005. 289:79-111. [Medline].
DeBiasi RL, Kleinschmidt-DeMasters BK, Richardson-Burns S, Tyler KL. Central nervous system apoptosis in human herpes simplex virus and cytomegalovirus encephalitis. J Infect Dis. 2002 Dec 1. 186(11):1547-57. [Medline].
Esiri MM. Herpes simplex encephalitis. An immunohistological study of the distribution of viral antigen within the brain. J Neurol Sci. 1982 May. 54(2):209-26. [Medline].
Cinque P, Vago L, Marenzi R, Giudici B, Weber T, Corradini R, et al. Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Clin Infect Dis. 1998 Aug. 27(2):303-9. [Medline].
Fodor PA, Levin MJ, Weinberg A, Sandberg E, Sylman J, Tyler KL. Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology. 1998 Aug. 51(2):554-9. [Medline].
Osih RB, Brazie M, Kanno M. Multifocal herpes simplex virus type 2 encephalitis in a patient with AIDS. AIDS Read. 2007 Feb. 17(2):67-70. [Medline].
Baringer JR, Pisani P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann Neurol. 1994 Dec. 36(6):823-9. [Medline].
Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol. 1996 Jan 1. 156(1):246-55. [Medline].
Geiger KD, Nash TC, Sawyer S, Krahl T, Patstone G, Reed JC, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology. 1997 Nov 24. 238(2):189-97. [Medline].
Zhang SY, Abel L, Casanova JL. Mendelian predisposition to herpes simplex encephalitis. Handb Clin Neurol. 2013. 112:1091-7. [Medline].
Menasria R, Boivin N, Lebel M, Piret J, Gosselin J, Boivin G. Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against HSV-1 infection. J Virol. 2013 Apr 17. [Medline].
Cathomas R, Pelosi E, Smart J, Murray N, Simmonds P. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer. Clin Oncol (R Coll Radiol). 2005 Jun. 17(4):292-3. [Medline].
Kohl S. Herpes Simplex Virus. In: Behrman RE, Kliegman RM, Jenson HB. Behrman: Nelson Textbook of Pediatrics. 17th ed. Philadelphia: Saunders; 2004.
Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes. 2004 Jun. 11 Suppl 2:65A-76A. [Medline].
Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. 1977 Aug 11. 297(6):289-94. [Medline].
Utley TF, Ogden JA, Gibb A, McGrath N, Anderson NE. The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. 1997 Jul. 10(3):180-9. [Medline].
Elbers JM, Bitnun A, Richardson SE, Ford-Jones EL, Tellier R, Wald RM, et al. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?. Pediatrics. 2007 Feb. 119(2):e399-407. [Medline].
Shelley BP, Raniga SB, Al-Khabouri J. An unusual late complication of intracerebral haematoma in herpes encephalitis after successful acyclovir treatment. J Neurol Sci. 2007 Jan 31. 252(2):177-80. [Medline].
Marschitz I, Rödl S, Gruber-Sedlmayr U, Church A, Giovannoni G, Zobel G, et al. Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis. J Neurol Neurosurg Psychiatry. 2007 Jan. 78(1):105-7. [Medline]. [Full Text].
Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006 Feb. 253(2):163-70. [Medline].
Ku A, Lachmann EA, Nagler W. Selective language aphasia from herpes simplex encephalitis. Pediatr Neurol. 1996 Sep. 15(2):169-71. [Medline].
McGrath NM, Anderson NE, Hope JK, Croxson MC, Powell KF. Anterior opercular syndrome, caused by herpes simplex encephalitis. Neurology. 1997 Aug. 49(2):494-7. [Medline].
Mondal G, Kumar R, Ghosh JK, Basu K, Chatterjee S. Basal ganglia involvement in a child with herpes simplex encephalitis. Indian J Pediatr. 2009 Jul. 76(7):749-50. [Medline].
Li JZ, Sax PE. HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read. 2009 Apr. 19(4):153-5. [Medline].
Benetó A, Gómez E, Rubio P, Sobrino R, Esparza A, Gil M, et al. [Periodical EEG pattern modifications in herpetic encephalitis treated with acyclovir]. Rev Neurol. 1996 Jul. 24(131):829-32. [Medline].
Mook-Kanamori B, van de Beek D, Wijdicks EF. Herpes simplex encephalitis with normal initial cerebrospinal fluid examination. J Am Geriatr Soc. 2009 Aug. 57(8):1514-5. [Medline].
Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. 2009 Aug. 81(8):1432-7. [Medline].
Domingues RB, Lakeman FD, Mayo MS, Whitley RJ. Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. 1998 Aug. 36(8):2229-34. [Medline]. [Full Text].
Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamadé U, Steinvorth S, Hacke W, et al. Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology. 1997 May. 48(5):1341-6. [Medline].
Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis. 2002 Apr 15. 34(8):1154-7. [Medline].
Benson PC, Swadron SP. Empiric acyclovir is infrequently initiated in the emergency department to patients ultimately diagnosed with encephalitis. Ann Emerg Med. 2006 Jan. 47(1):100-5. [Medline].
Rathmann K, Scott SA. Acyclovir. Undefined. In: Drug Evaluation Monographs. Micromedex:2005.
Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004 Apr. 70(4):201-7. [Medline].
James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res. 2009 Sep. 83(3):207-13. [Medline]. [Full Text].
National Institute of Allergy and Infectious Diseases. A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct/show/NCT00031486?order=1. Accessed: August 8, 2007.
Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009 Jan 21. CD006706. [Medline].
Sergerie Y, Boivin G, Gosselin D, Rivest S. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J Infect Dis. 2007 Mar 15. 195(6):817-25. [Medline].
Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000 Feb. 6(1):25-32. [Medline].
Kamei S, Sekizawa T, Shiota H, Mizutani T, Itoyama Y, Takasu T, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005 Nov. 76(11):1544-9. [Medline]. [Full Text].
Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 2008 Oct 29. 8:40. [Medline]. [Full Text].
Pérez de Diego R, Mulvey C, et al. The proteome of Toll-like receptor 3-stimulated human immortalized fibroblasts: implications for susceptibility to herpes simplex virus encephalitis. J Allergy Clin Immunol. 2013 Apr. 131(4):1157-66. [Medline]. [Full Text].
Schleede L, Bueter W, Baumgartner-Sigl S, Opladen T, Weigt-Usinger K, Stephan S, et al. Pediatric herpes simplex virus encephalitis: a retrospective multicenter experience. J Child Neurol. 2013 Mar. 28(3):321-31. [Medline].

Media Gallery

Axial proton density-weighted image in 62-year-old woman with confusion and herpes encephalitis shows T2 hyperintensity involving right temporal lobe.
Axial gadolinium-enhanced T1-weighted image reveals enhancement of right anterior temporal lobe and parahippocampal gyrus. At right anterior temporal tip is hypointense, crescentic region surrounded by enhancement consistent with small epidural abscess.
Axial diffusion-weighted image reveals restricted diffusion in left medial temporal lobe consistent with herpes encephalitis. This patient also had positive result on polymerase chain reaction assay for herpes simplex virus, which is both sensitive and specific. In addition, patient had periodic lateralized epileptiform discharges on electroencephalography, which supports diagnosis of herpes encephalitis.

of 3

Author

Wayne E Anderson, DO, FAHS, FAAN Assistant Professor of Internal Medicine/Neurology, College of Osteopathic Medicine of the Pacific Western University of Health Sciences; Clinical Faculty in Family Medicine, Touro University College of Osteopathic Medicine; Clinical Instructor, Departments of Neurology and Pain Management, California Pacific Medical Center

Wayne E Anderson, DO, FAHS, FAAN is a member of the following medical societies: American Academy of Neurology, American Headache Society, California Medical Association, California Neurology Society, International Headache Society, San Francisco Medical Society, San Francisco Neurological Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Alliance, Bioserenity, Ceribell, Eisai, Greenwich, LivaNova, Neurelis, Neuropace, Nexus, RSC, SK life science, Sunovion<br/>Serve(d) as a speaker or a member of a speakers bureau for: Alliance, Aquestive, Bioserenity, Eisai, Greenwich, LivaNova, Neurelis, SK life science, Sunovion<br/>Received research grant from: Cerevel, LivaNova, Greenwich, SK biopharmaceuticals, Takeda.

Chief Editor

Niranjan N Singh, MBBS, MD, DM, FAHS, FAANEM Adjunct Associate Professor of Neurology, University of Missouri-Columbia School of Medicine; Medical Director of St Mary's Stroke Program, SSM Neurosciences Institute, SSM Health

Niranjan N Singh, MBBS, MD, DM, FAHS, FAANEM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Headache Society

Disclosure: Nothing to disclose.

Additional Contributors

Ramon Diaz-Arrastia, MD, PhD Professor, Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School; Director, North Texas TBI Research Center, Comprehensive Epilepsy Center, Parkland Memorial Hospital

Ramon Diaz-Arrastia, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, New York Academy of Sciences, Phi Beta Kappa

Disclosure: Nothing to disclose.

Herpes Simplex Encephalitis Medication

Medication Summary

Antivirals

Class Summary

Acyclovir (Zovirax)

Acyclovir (Zovirax)

Famciclovir (Famvir)

Famciclovir (Famvir)

Anticonvulsants

Class Summary

Carbamazepine (Tegretol)

Carbamazepine (Tegretol)

Phenytoin (Dilantin, Phenytek)

Phenytoin (Dilantin, Phenytek)

Diuretics

Class Summary

Furosemide (Lasix)

Furosemide (Lasix)

Mannitol (Osmitrol)

Mannitol (Osmitrol)

Herpes Simplex Encephalitis Medication

Medication Summary

Antivirals

Class Summary

Acyclovir (Zovirax)

Acyclovir (Zovirax)

Famciclovir (Famvir)

Famciclovir (Famvir)

Anticonvulsants

Class Summary

Carbamazepine (Tegretol)

Carbamazepine (Tegretol)

Phenytoin (Dilantin, Phenytek)

Phenytoin (Dilantin, Phenytek)

Diuretics

Class Summary

Furosemide (Lasix)

Furosemide (Lasix)

Mannitol (Osmitrol)

Mannitol (Osmitrol)

References

Tables

Contributor Information and Disclosures

What would you like to print?